More Indications for the Use of GnRH Antagonists
|Horowitz E, Ravhon A, Nahum H, Golan A, Levran D and Weissman A*|
|IVF Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel|
|*Corresponding Author :||Ariel Weissman, MD
IVF Unit, Department of Obstetrics and Gynecology
Edith Wolfson Medical Center, Holon, Israel
E-mail: [email protected]
|Received June 27, 2013; Accepted July 27, 2013; Published July 29, 2013|
|Citation: Horowitz E, Ravhon A, Nahum H, Golan A, Levran D, et al. (2013) More Indications for the Use of GnRH Antagonists.J Fertil In Vitro IVF Worldw Reprod Med Genet Stem Cell Biol 1:107. doi:10.4172/2375-4508.1000107|
|Copyright: © 2013 Horowitz E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Purpose: Due to their ability to effectively suppress the LH surge, the primary use of GnRH antagonists is to prevent premature luteinization and ovulation during ovarian stimulation. We describe two cases which represent new indications for the use of GnRH antagonist that may prevent distressing complications associated with infertility therapy.
Methods: A 25-year-old anovulatory woman with PCOS who was treated with clomiphene citrate exhibited an excessive response. The second case involved a 45-year-old egg recipient who underwent hormonal preparation with estradiol valerate. At an early stage of treatment a dominant follicle developed that could result in undesired premature ovulation and cycle cancellation. A GnRH antagonist was administered in both cases.
Results: In the first case OHSS was prevented, and a singleton pregnancy was achieved. In the second case, spontaneous ovulation was avoided and a singleton pregnancy was accomplished as well.
Conclusions: GnRH antagonists can be used for the prevention of distressing complications of clomiphene citrate treatment and for the prevention of unwanted spontaneous ovulation during hormonal preparation in oocyte recipients.